Related Experiment Video
Updated: Aug 11, 2026
Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer
Published on: May 20, 2016
Specific association of MTHFD1 expressions with small cell lung cancer development and chemoradiotherapy outcome
Yujia Hao1, Ruichun Lu1, Ying Guo1
1From the Department of Respiratory Medicine Second Ward (Hao), JinanThird People's Hospital, Jinan, from the Department of Cadre Healthcare/Geriatrics (Lu), Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, from the Hebei North University (Guo), Zhangjiakou, and from the Department of Pulmonary and Critical Care Medicine (Bao), The Eighth Medical Center of Chinese PLA General Hospital, Beijing, China.
Objectives:
To identify biomarkers that can discriminated small cell lung cancer (SCLC) from non-SCLC (NSCLC), and explore their association with the prognosis of SCLC under chemoradiotherapy.
Methods:
The GSE40275 dataset was used to identify potential targets in SCLC. There were 196 patients of lung cancer (LC) in cohort 1 of this study. MTHFD1 levels in tissues were determined by immunohistochemistry assay in cohort 1. Lung cancer patients who were all underwent local chemoradiotherapy (CRT) were included in cohort 2, and the association of MTHFD1 levels with CRT treatment outcome were determined in cohort 2. Cell experiments were used to determine the function of MTHFD1 on the radio-sensitivity of SCLC and NSCLC cells.
Results:
The MTHFD1 levels in LC tissues were increased, and could discriminate SCLC from both lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD). Small cell lung cancer patients with MTHFD1 high phenotype had a poorer prognosis after CRT treatment, whereas no significant correlation was found between MTHFD1 levels and prognosis in LUSC and LUAD group. Cell experiments demonstrated that overexpression of MTHFD1 increases radio-resistance in both SCLC and NSCLC in vitro.
Conclusion:
MTHFD1 expressions might be a novel specifically prognostic biomarker for SCLC and the CRT treatment outcome.
